Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) announces data presentations at AAD Annual Meeting showcasing improved survival in patients with cutaneous melanoma using DecisionDx-Melanoma test. The company's gene expression profile tests demonstrate effectiveness in guiding personalized care for skin cancer patients.

Positive

• Castle Biosciences presents findings at AAD Annual Meeting confirming DecisionDx-Melanoma test improves survival in patients with cutaneous melanoma.
• Data from a study of over 5,000 patients supports the efficacy of Castle's gene expression profile tests in guiding patient care.
• Abstracts presented at AAD highlight the use of DecisionDx-Melanoma and DecisionDx-SCC tests in improving risk assessment and treatment decisions for skin cancer patients.
• Castle's MyPath Melanoma diagnostic test aids in diagnosing invasive melanoma, reducing overdiagnosis and overtreatment for challenging lesions.
• The company's collaborations with leading dermatologists aim to empower clinicians and patients with actionable information for better outcomes.

Negative

• None.

Oncology Doctor

The study on the DecisionDx-Melanoma test is a significant advancement in the management of cutaneous melanoma (CM), particularly for patients under the age of 65. From an oncological perspective, the ability to stratify patients based on their risk of melanoma-specific death is crucial. Aggressive management strategies, such as increased imaging surveillance for those identified as high-risk, can lead to earlier detection of recurrence. This is important because lower tumor burdens are generally associated with better responses to treatment. The implications of this study are substantial, as they could lead to a shift in how younger CM patients are monitored post-diagnosis, potentially improving survival rates.

Medical Research Analyst

The data presented on the DecisionDx-SCC (40-GEP) test contributes to the field of precision medicine. The utilization of the test in clinical settings indicates that it is being adopted according to intended use indications, which is pivotal for the test's credibility and applicability in high-risk cutaneous squamous cell carcinoma (cSCC) cases. Over 70% of patients being classified as lower biological risk for metastasis (Class 1) suggests that the test could be effective in reducing overtreatment. Furthermore, the test's ability to provide independent risk assessment from clinicopathological presentation supports its integration into clinical decision-making processes. This could lead to more personalized treatment plans, which is a key goal in modern oncology.

Market Research Analyst

Castle Biosciences' presentations at the AAD Annual Meeting showcase the company's commitment to innovation in dermatologic diagnostics. The clinical adoption of their gene expression profile (GEP) tests, such as DecisionDx-Melanoma and DecisionDx-SCC, reflects positively on the company's market position. By demonstrating the clinical utility of these tests, Castle Biosciences could see increased demand from healthcare providers seeking to improve patient outcomes. This could potentially lead to sustained revenue growth as the tests become standard practice in the management of skin cancers. Moreover, the company's ability to leverage existing RNA-based testing in the diagnostic workflow to provide quick, actionable results with the MyPath Melanoma test further strengthens its competitive edge in the precision medicine space.

Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program Registries, providing new data from a study of more than 5,000 patients confirming that testing with DecisionDx®-Melanoma is associated with improved survival in patients with cutaneous melanoma (CM)

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share data across its dermatologic portfolio of gene expression profile (GEP) tests via oral and electronic poster presentations at the 2024 AAD Annual Meeting, taking place March 8-12 in San Diego.

“Our presentations at the 2024 AAD Annual Meeting add to the growing body of evidence supporting the use of our tests in guiding improved, personalized care for patients with skin cancers,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “In collaboration with leading dermatologists dedicated to advancing patient care, we are excited to share our latest findings which highlight how our tests are empowering both clinicians and patients with meaningful, clinically actionable information that can refine risk and inform important treatment decisions.”

Castle will present the following abstracts at AAD. Abstract content will be available throughout the meeting in the online viewing portal and at the on-site viewing stations, and will also be published online in the Fall 2024 Journal of the American Academy of Dermatology (JAAD) supplement.

DecisionDx®-Melanoma

• Oral Poster Presentation Title: 31-GEP testing is associated with improved melanoma-specific survival relative to untested patients: an analysis of patients <65 years old
• Presenter and Lead Author: Michael Tassavor, M.D., Skin Cancer Center, Cincinnati
• Abstract Number: 51667
• Date: March 9, 2024
• Time: 4:50-4:55 p.m. Pacific Time
• Location: San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)

Summary: For patients with CM, the median age at diagnosis is 66 years old, suggesting that almost half of newly diagnosed patients are younger than 65. In this large study of unselected, clinically tested patients with CM who were under 65 (n=5,183), the DecisionDx-Melanoma (31-GEP) test identified patients at higher risk of melanoma-specific death who may benefit from more aggressive management, including imaging surveillance. In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients. This is clinically significant, as identifying high-risk patients allows for earlier detection of recurrence, while the tumor burden is lower, which has been shown to lead to better response to therapy.

DecisionDx®-SCC

• Oral Poster Presentation Title: Consistent utilization of the 40-gene expression profile (40-GEP) test in high-risk cutaneous squamous cell carcinoma (cSCC) by clinicians according to intended use indications
• Presenter and Lead Author: Jane Yoo, M.D., Icahn School of Medicine at Mount Sinai, New York
• Abstract Number: 54153
• Date: March 9, 2024
• Time: 10:30-10:35 a.m. Pacific Time
• Location: San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)

Summary: This study provides summary metrics regarding DecisionDx-SCC (40-GEP) test results and patient risk factors for tumor samples clinically tested in the first three years of the test’s availability between September 2020 and August 2023 (n=16,930). The study data demonstrate that clinicians are utilizing the DecisionDx-SCC test appropriately for patients with high-risk cutaneous squamous cell carcinoma (SCC). These patients are at a higher risk of poor outcomes compared to the general SCC patient population, yet over 70% of patients received a Decision-SCC Class 1 test result, indicating they are at a lower biological risk for metastasis. Each DecisionDx-SCC Class result was present in the various subgroupings of risk factors in the study (patients with 1-2, 3-4 and more than 5 risk factors), demonstrating that the test provides independent risk assessment from clinicopathological presentation. These data support incorporating the test’s results into clinical practice to improve the accuracy of risk predictions to guide more personalized treatment plans for patients.

MyPath® Melanoma

• ePoster Title: Enabling access to prognostic gene expression profile (GEP) testing for invasive melanoma by leveraging RNA-based testing in the diagnostic workflow
• Abstract Number: 52819

Summary: Reaching a definitive diagnosis of melanoma can be challenging. Ancillary testing can provide clarity and a definitive diagnosis for problematic lesions. The MyPath Melanoma (23-GEP) diagnostic test returns accurate results quickly, with approximately 80% of cases tested receiving an actionable result in a median of four business days. Between March 1 and July 31, 2023, approximately 60% of ambiguous lesions tested with MyPath received a benign test result, potentially reducing overdiagnosis and overtreatment for diagnostically challenging lesions. Lesions that receive a malignant test result (approximately 20% of lesions tested with MyPath in the five-month study timeframe) can be tested with the DecisionDx-Melanoma risk stratification test, using the same extracted tumor material when available, to inform risk-aligned decisions about sentinel lymph node biopsy, surveillance imaging and patient follow-up schedules. Approximately 80% of clinically tested lesions with a malignant MyPath result have sufficient biopsy tumor content for DecisionDx-Melanoma testing.

About DecisionDx-Melanoma

DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through Dec. 31, 2023, DecisionDx-Melanoma has been ordered more than 150,000 times for patients diagnosed with cutaneous melanoma.

About DecisionDx-SCC

DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1 (low), Class 2A (higher) or Class 2B (highest) risk category, predicts individual metastatic risk to inform risk-appropriate management. Peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.

About MyPath Melanoma

MyPath Melanoma is Castle’s gene expression profile test designed to provide an accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions. Of the approximately two million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. For these cases, the treatment plan can also be uncertain. Obtaining accurate, objective ancillary testing can mean the difference between a path of overtreatment or the risk of undertreatment. Interpreted in the context of other clinical, laboratory and histopathologic information, MyPath Melanoma is designed to reduce uncertainty and provide confidence for dermatopathologists and help dermatologists deliver more informed patient management plans.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of our tests to (i) guide improved, personalized care for patients with skin cancers and (ii) provide meaningful, clinically actionable information that can refine risk and inform important treatment decisions. The words “believe,” “can” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240308635392/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com



Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

How many patients were included in the study confirming improved survival in cutaneous melanoma patients using DecisionDx-Melanoma test?

The study included data from more than 5,000 patients.

What is the abstract number for the DecisionDx-Melanoma oral poster presentation at AAD?

The abstract number for the DecisionDx-Melanoma presentation is 51667.

What percentage of patients with high-risk cutaneous squamous cell carcinoma received a Decision-SCC Class 1 test result?

Over 70% of patients received a Decision-SCC Class 1 test result.

How quickly do approximately 80% of cases tested with MyPath Melanoma receive an actionable result?

Approximately 80% of cases tested with MyPath receive an actionable result in a median of four business days.

Which test can be used for risk stratification in lesions that receive a malignant test result with MyPath Melanoma?

The DecisionDx-Melanoma risk stratification test can be used for risk-aligned decisions in lesions that receive a malignant test result with MyPath Melanoma.